COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance

Sabine Bou-Antoun; Sakib Rokadiya; Diane Ashiru-Oredope; Alicia Demirjian; Emma Sherwood; Nicholas Ellaby; Sarah Gerver; Carlota Grossi; Katie Harman; Hassan Hartman; Alessandra Lochen; Manon Ragonnet-Cronin; Hanna Squire; J. Mark Sutton; Simon Thelwall; Julia Tree; Mohammad W. Bahar; David I. Stuart; Colin S. Brown; Meera Chand; Susan Hopkins

doi:10.1093/jac/dkad314

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance

Sabine Bou-Antoun^*, Sakib Rokadiya, Diane Ashiru-Oredope, Alicia Demirjian, Emma Sherwood, Nicholas Ellaby, Sarah Gerver, Carlota Grossi, Katie Harman, Hassan Hartman, Alessandra Lochen, Manon Ragonnet-Cronin, Hanna Squire, J. Mark Sutton, Simon Thelwall, Julia Tree, Mohammad W. Bahar, David I. Stuart, Colin S. Brown, Meera ChandSusan Hopkins

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.

Original language	English
Pages (from-to)	II37-II42
Journal	Journal of Antimicrobial Chemotherapy
Volume	78
DOIs	https://doi.org/10.1093/jac/dkad314
Publication status	Published - 1 Nov 2023

Bibliographical note

Publisher Copyright:
© 2023 Oxford University Press. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkad314

Cite this

Bou-Antoun, S., Rokadiya, S., Ashiru-Oredope, D., Demirjian, A., Sherwood, E., Ellaby, N., Gerver, S., Grossi, C., Harman, K., Hartman, H., Lochen, A., Ragonnet-Cronin, M., Squire, H., Sutton, J. M., Thelwall, S., Tree, J., Bahar, M. W., Stuart, D. I., Brown, C. S., ... Hopkins, S. (2023). COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 78, II37-II42. https://doi.org/10.1093/jac/dkad314

@article{c166aed6a63149c69eeed70d6392fe9e,

title = "COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance",

abstract = "The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.",

author = "Sabine Bou-Antoun and Sakib Rokadiya and Diane Ashiru-Oredope and Alicia Demirjian and Emma Sherwood and Nicholas Ellaby and Sarah Gerver and Carlota Grossi and Katie Harman and Hassan Hartman and Alessandra Lochen and Manon Ragonnet-Cronin and Hanna Squire and Sutton, {J. Mark} and Simon Thelwall and Julia Tree and Bahar, {Mohammad W.} and Stuart, {David I.} and Brown, {Colin S.} and Meera Chand and Susan Hopkins",

year = "2023",

month = nov,

day = "1",

doi = "10.1093/jac/dkad314",

language = "English",

volume = "78",

pages = "II37--II42",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

}

Bou-Antoun, S, Rokadiya, S, Ashiru-Oredope, D, Demirjian, A, Sherwood, E, Ellaby, N, Gerver, S, Grossi, C, Harman, K, Hartman, H, Lochen, A, Ragonnet-Cronin, M, Squire, H, Sutton, JM , Thelwall, S , Tree, J, Bahar, MW, Stuart, DI, Brown, CS , Chand, M & Hopkins, S 2023, 'COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance', Journal of Antimicrobial Chemotherapy, vol. 78, pp. II37-II42. https://doi.org/10.1093/jac/dkad314

TY - JOUR

T1 - COVID-19 therapeutics

T2 - stewardship in England and considerations for antimicrobial resistance

AU - Bou-Antoun, Sabine

AU - Rokadiya, Sakib

AU - Ashiru-Oredope, Diane

AU - Demirjian, Alicia

AU - Sherwood, Emma

AU - Ellaby, Nicholas

AU - Gerver, Sarah

AU - Grossi, Carlota

AU - Harman, Katie

AU - Hartman, Hassan

AU - Lochen, Alessandra

AU - Ragonnet-Cronin, Manon

AU - Squire, Hanna

AU - Sutton, J. Mark

AU - Thelwall, Simon

AU - Tree, Julia

AU - Bahar, Mohammad W.

AU - Stuart, David I.

AU - Brown, Colin S.

AU - Chand, Meera

AU - Hopkins, Susan

PY - 2023/11/1

Y1 - 2023/11/1

N2 - The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.

AB - The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85177803382&partnerID=8YFLogxK

U2 - 10.1093/jac/dkad314

DO - 10.1093/jac/dkad314

M3 - Article

C2 - 37995354

AN - SCOPUS:85177803382

SN - 0305-7453

VL - 78

SP - II37-II42

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

ER -

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this